Tag: TACE

Transarterial #chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic #hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study

aledopress

BackgroundTransarterial chemoembolisation (TACE) is standard care for unresectable, non-metastatic hepatocellular carcinoma. We aimed to evaluate the addition of lenvatinib and pembrolizumab to TACE versus dual placebo plus TACE in patients with unresectable, non-metastatic hepatocellular carcinoma.MethodsIn this multicentre, randomised, double-blind, phase 3 study (LEAP-012), patients were recruited from 137 global sites in 33 countries or regions.… Continue reading Transarterial #chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic #hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study